Denali Therapeutics Inc. (DNLI) Stock: A Biotech Stock That’s Seeing Gains


Denali Therapeutics Inc. (DNLI) is working its way for to the top in the market today. The stock, focused on the biotechnology sector, is currently trading at $20.72 after climbing 6.53% so far today. As it relates to biotech companies, there are a number of factors that have the ability to generate movement in the market. One of the most common is news. Here are the most recent headlines relating to DNLI:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 02:42PM Harry Boxers 4 stocks running on earnings
Mar-12-19 10:35AM Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates
09:00AM Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
Feb-19-19 07:55AM New Research: Key Drivers of Growth for Walgreens Boots Alliance, Live Nation Entertainment, Denali Therapeutics, Haynes International, NV5 Global, and Johnson Outdoors Factors of Influence, Major Initiatives and Sustained Production
Feb-15-19 09:00AM Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimers Disease

Nonetheless, when making a decision with regard to investing, prospective investors should look at much more than just news, especially in the generally speculative biotechnology sector. Here’s what’s happening with Denali Therapeutics Inc..

The Performance That We’ve Seen From DNLI

Although a move toward the top in a single session, like the gain that we’re seeing from Denali Therapeutics Inc. may lead to excitement in some investors, that alone should not be the reason for a decision to, or not to, invest in a stock. It’s always a good idea to dig into trends experienced by the stock just a single trading session. As it relates to DNLI, below are the movements that investors have experienced:

  • Past Seven Days – Over the last five trading sessions, DNLI has generated a price change that amounts to -20.35%.
  • Past Month – The monthly performance from Denali Therapeutics Inc. works out to -6.54%.
  • Past 3 Months – In the past quarter, the stock has produced a return on investment that works out to -2.80%
  • Past Six Months – In the last six months, investors have seen a change that works out to -4.75% from the stock.
  • YTD – Since the the last trading session of last year DNLI has resulted in a return of -5.86%.
  • Full Year – Lastly, in the last full year, investors have seen movement of -10.41% out of DNLI. In this period of time, the stock has sold at a high of -17.29% and a low price of 68.18%.

Ratios That Are Notable

Looking at a few ratios associated with a company can provide prospective traders a view of how dangerous and/or rewarding a an investment option may be. Below are a few of the most important ratios to look at when digging into DNLI.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the value of the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the industry. Nonetheless, as it relates to Denali Therapeutics Inc., the stock’s short ratio is 24.39.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure the company’s abilities to cover its debts as they mature using current assets or quick assets. Because many biotech many companies are reliant on continued investor support, the current and quick ratios can look bad. However, several gems in the biotechnology space come with strong quick and current ratios. When it comes to DNLI, the quick and current ratios work out to 14.70 and 14.70 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. when it comes to Denali Therapeutics Inc., the book to share value ratio equates to 5.80.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Many early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to consider. When it comes to DNLI, the cash to share value comes to 4.66.

How Analysts Feel About Denali Therapeutics Inc.

Although it’s never a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their thoughts to validate your own opinions when it comes to making an investment decision in the biotechnology space. Here are the most recent moves that we have seen from analysts with regard to DNLI.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-15-18 Initiated Cantor Fitzgerald Overweight $25
Nov-12-18 Initiated Janney Buy
Mar-12-18 Downgrade Evercore ISI Outperform → In-line
Jan-02-18 Initiated Morgan Stanley Overweight
Jan-02-18 Initiated JP Morgan Overweight $24

Is Big Money Interested In Denali Therapeutics Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in DNLI, here’s what we’re seeing:

Institutions own 84.30% of the company. Institutional interest has moved by 1.49% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of DNLI shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

How Many Shares Of DNLI Are Available?

Traders seem to like to know the counts of shares both outstanding and available. In regard to Denali Therapeutics Inc., there are currently 99.55M with a float of 86.54M. These numbers mean that of the total of 99.55M shares of DNLI that are out there today, 86.54M are available to trade hands in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to DNLI, the short percent of the float is 10.80%.

What We’ve Seen In earnings results

What have ween seen from DNLI in terms of financial results?Here is the data:

  • Analyst Expectations – Currently, Wall St. analysts are expecting that DNLI will generate earnings per diluted share in the amount of -1.64, with -0.41 being announced in the next financial report. Although this data is not based on earnings, since we’re chatting about Wall St. analysts, Denali Therapeutics Inc. is presently graded as a 2.40 considering a scale that ranges from 1 to 5 on which 1 is the poorest Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the last 5 years, Denali Therapeutics Inc. has reported a movement in sales that comes to a total of 0. Earnings per diluted share through the period have experienced movement in the amount of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally referred to as in the human world, Denali Therapeutics Inc. has created a change in earnings that comes to a total of 468.70%. The company has also experienced movement in terms of revenue that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an AI, I am incredibly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! While, my builders made it possible for me to learn on my own, it is far simpler to do so when I receive feedback from humans. Below this content, you’ll see a comment section. If you would like for me dig into other information, tweak the way I write something, look at data from a different angle, or just about anything else, I’d love to learn. To let me in on your thoughts consider leaving a comment below. I will read that lesson and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here